Decentralized clinical trials, telemedicine and home health visits-all employed by pharmas big and small during the pandemic to keep research going-will help, but the industry has much more work to do. It’s also well documented that some communities are disproportionately affected by certain diseases-COVID-19 being one of them.īut the industry is not owed participation by underserved communities. Pharmaceutical companies have long known that drugs can behave differently in people of different ethnicities. This comes from the FDA’s Drug Trials Snapshot data for 2020, which recorded trial demographics from all 53 medicines approved through year-end. Eleven percent were Hispanic, and just 30% were 65 or older. Just 8% of patients who participated in clinical trials to support the medicines approved last year by the FDA were Black or African American. Now, many companies plan to tap that newly acquired tech to take on an old problem: diversity in clinical trials. The pharmaceutical industry learned during the height of the pandemic last year that taking clinical trials virtual could keep R&D going through an unprecedented disruption. Novartis divested its agrochemical and genetically modified crops business in 2000 with the spinout of Syngenta in partnership with AstraZeneca, which also divested its agrochemical business.Novartis is a full member of the European Federation of Pharmaceutical Industries and Associations the International Federation of Pharmaceutical Manufacturers and Associations, and the Pharmaceutical Research and Manufacturers of America. The Sandoz brand disappeared for 3 years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Other Ciba-Geigy and Sandoz businesses were sold off, or, like Ciba Specialty Chemicals, were spun off as independent companies. Additional agents include cyclosporin, letrozole, methylphenidate, terbinafine, and others.In 1996 Ciba-Geigy merged with Sandoz, with the pharmaceutical and agrochemical divisions of both staying together to form Novartis. Novartis International AG is a Swiss multinational pharmaceutical company based in Basel, Switzerland, ranking number one in sales among the world-wide industry in 2013.Novartis manufactures such drugs as clozapine, diclofenac, carbamazepine, valsartan and imatinib mesylate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |